Monitoring therapy response of experimental arthritis with radiolabeled tracers targeting fibroblasts, macrophages, or integrin αvβ3

Journal of Nuclear Medicine

Volumn 57, Issue 3, 2016, Pages 467-472

  Terry, Samantha Y A ^a,b   Koenders, Marije I ^a   Franssen, Gerben M ^a   Nayak, Tapan K ^c   Freimoser Grundschober, Anne ^d   Klein, Christian ^d   Oyen, Wim J ^a   Boerman, Otto C ^a   Laverman, Peter ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d Roche Pharmaceutical Research and Early Development   (Switzerland)

Author keywords

Experimental arthritis; Fibroblast activation protein; Macrophages; RGD peptide; Therapy response

Indexed keywords

CELL PROTEIN; ETANERCEPT; FIBROBLAST ACTIVATION PROTEIN; MONOCLONAL ANTIBODY 28H1 IN 111; MONOCLONAL ANTIBODY F4 80 A3 1 IN 111; RGD2 IN 111; TRACER; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ARGINYL-GLYCYL-ASPARTIC ACID; OLIGOPEPTIDE; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLAGEN-INDUCED ARTHRITIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CT-SPECT SCANNER; DRUG RESPONSE; FIBROBLAST; ISOTOPE LABELING; MACROPHAGE; MALE; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE DISTRIBUTION; ANIMAL; ARTHRITIS, EXPERIMENTAL; CYTOLOGY; DBA MOUSE; JOINT; METABOLISM; POSITRON EMISSION TOMOGRAPHY; RAT; SCINTISCANNING; SYNOVIAL FLUID;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ETANERCEPT; FIBROBLASTS; INTEGRIN ALPHAVBETA3; JOINTS; MACROPHAGES; MALE; MICE; MICE, INBRED DBA; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; SYNOVIAL FLUID; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84960092057     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.162628     Document Type: Article

References (42)

1. Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: Estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73: 1316-1322.
2. Rheumatoid arthritis: The management of rheumatoid arthritis in adults. NICE clinical guideline 79. National Institute for Health and Care Excellence website. https://www.nice.org.uk/guidance/cg79. Modified August 2013. Accessed January 5, 2016.
3. Firth J. Rheumatoid arthritis: Treating to target with disease-modifying drugs. Br J Nurs. 2011;20: 1240-1245.
4. Brown PM, Isaacs JD. Rheumatoid arthritis: From palliation to remission in two decades. Clin Med. 2014;14(suppl 6): S50-s55.
5. Dougados M, Nataf H, Steinberg G, Rouanet S, Falissard B. Relative importance of doctor-reported outcomes vs patient-reported outcomes in DMARD intensification for rheumatoid arthritis: The DUO study. Rheumatology (Oxford). 2013;52: 391-399.
6. Firestein GS. Invasive fibroblast-like synoviocytes in rheumatoid arthritis; passive responders or transformed aggressors? Arthritis Rheum. 1996;39: 1781-1790.
7. Bauer S, Jendro MC, Wadle A, et al. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res Ther. 2006;8: R171.
8. Laverman P, van der Geest T, Terry SY, et al. Immuno-PET and immuno-SPECT of rheumatoid arthritis with radiolabeled anti-fibroblast activation protein antibody correlates with severity of arthritis. J Nucl Med. 2015;56: 778-783.
9. Le Goff B, Berthelot JM, Maugars Y, Heymann D. Osteoclasts in RA: Diverse origins and functions. Joint Bone Spine. 2013;80: 586-591.
10. Zheleznyak A, Wadas TJ, Sherman CD, et al. Integrin avb3 as a PET imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulation. Mol Imaging Biol. 2012;14: 500-508.
11. Bender AT, Spyvee M, Satoh T, et al. Evaluation of a candidate anti-arthritic drug using the mouse collagen antibody induced arthritis model and clinically relevant biomarkers. Am J Transl Res. 2013;5: 92-102.
12. Terry SY, Abiraj K, Frielink C, et al. Imaging integrin avb3 on blood vessels with 111In-RGD2 in head and neck tumor xenografts. J Nucl Med. 2014;55: 281-286.
13. Terry SYA, Boerman OC, Gerrits D, et al. 111In-anti-F4/80-A3-1 antibody: A novel tracer to image macrophages. Eur J Nucl Med Mol Imaging. 2015;42: 1430-1438.
14. Rosado-de-Castro PH, Lopes de Souza SA, Alexandre D, Barbosa da Fonseca LM, Gutfilen B. Rheumatoid arthritis: Nuclear medicine state-of-Theart imaging. World J Orthop. 2014;5: 312-318.
15. Tan YK, Conaghan PG. Imaging in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2011;25: 569-584.
16. Weis SM, Cheresh DA. Tumor angiogenesis: Molecular pathways and therapeutic targets. Nat Med. 2011;17: 1359-1370.
17. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7: 429-442.
18. Dijkgraaf I, Terry SY, McBride WJ, et al. Imaging integrin alpha-v-beta-3 expression in tumors with an 18F-labeled dimeric RGD peptide. Contrast Media Mol Imaging. 2013;8: 238-245.
19. Murray KM, Dahl SL. Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR: Fc) in rheumatoid arthritis. Ann Pharmacother. 1997;31: 1335-1338.
20. Pattacini L, Boiardi L, Casali B, Salvarani C. Differential effects of anti-TNFalpha drugs on fibroblast-like synoviocyte apoptosis. Rheumatology (Oxford). 2010;49: 480-489.
21. Mok CC, van der Kleij D, Wolbink GJ. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFa biologics in rheumatic diseases. Clin Rheumatol. 2013;32: 1429-1435.
22. Yi H, Kim J, Jung H, et al. Induced production of anti-etanercept antibody in collagen-induced arthritis. Mol Med Rep. 2014;9: 2301-2308.
23. Verel I, Heider KH, Siegmund M, et al. Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts. Int J Cancer. 2002;99: 396-402.
24. van Gog FB, Brakenhoff RH, Snow GB, van Dongen GA. Rapid elimination of mouse/human chimeric monoclonal antibodies in nude mice. Cancer Immunol Immunother. 1997;44: 103-111.
25. Catrina AI, Trollmo C, af Klint E, et al. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended report. Arthritis Rheum. 2005;52: 61-72.
26. Kameda H. Inhibition of the joint destruction in RA by TNF-blocking agents [article in Japanese]. Clin Calcium. 2007;17: 553-560.
27. Yago T, Nanke Y, Kawamoto M, et al. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther. 2007;9: R96.
28. Paleolog E. Target effector role of vascular endothelium in the inflammatory response: Insights from the clinical trial of anti-TNF alpha antibody in rheumatoid arthritis. Mol Pathol. 1997;50: 225-233.
29. Jamar F, Chapman PT, Harrison AA, Binns RM, Haskard DO, Peters AM. Inflammatory arthritis: Imaging of endothelial cell activation with an indium-111- labeled F(ab')2 fragment of anti-E-selectin monoclonal antibody. Radiology. 1995;194: 843-850.
30. Put S, Westhovens R, Lahoutte T, Matthys P. Molecular imaging of rheumatoid arthritis: Emerging markers, tools, and techniques. Arthritis Res Ther. 2014;16: 208.
31. Turk MJ, Breur GJ, Widmer WR, et al. Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis. Arthritis Rheum. 2002;46: 1947-1955.
32. Gent YY, Weijers K, Molthoff CF, et al. Evaluation of the novel folate receptor ligand [18F]fluoro-PEG-folate for macrophage targeting in a rat model of arthritis. Arthritis Res Ther. 2013;15: R37.
33. Piscaer TM, Muller C, Mindt TL, et al. Imaging of activated macrophages in experimental osteoarthritis using folate-targeted animal single-photon-emission computed tomography/computed tomography. Arthritis Rheum. 2011;63: 1898-1907.
34. van der Laken CJ, Elzinga EH, Kropholler MA, et al. Noninvasive imaging of macrophages in rheumatoid synovitis using 11C-(R)-PK11195 and positron emission tomography. Arthritis Rheum. 2008;58: 3350-3355.
35. Gent YY, Voskuyl AE, Kloet RW, et al. Macrophage positron emission tomography imaging as a biomarker for preclinical rheumatoid arthritis: Findings of a prospective pilot study. Arthritis Rheum. 2012;64: 62-66.
36. Pottier G, Bernards N, Dolle F, Boisgard R. [18F]DPA-714 as a biomarker for positron emission tomography imaging of rheumatoid arthritis in an animal model. Arthritis Res Ther. 2014;16: R69.
37. Zheng F, Put S, Bouwens L, et al. Molecular imaging with macrophage CRIgtargeting nanobodies for early and preclinical diagnosis in a mouse model of rheumatoid arthritis. J Nucl Med. 2014;55: 824-829.
38. Eichendorff S, Svendsen P, Bender D, et al. Biodistribution and PET imaging of a novel [Ga]-anti-CD163-antibody conjugate in rats with collagen-induced arthritis and in controls. Mol Imaging Biol. 2015;17: 87-93.
39. Put S, Schoonooghe S, Devoogdt N, et al. SPECT imaging of joint inflammation with Nanobodies targeting the macrophage mannose receptor in a mouse model for rheumatoid arthritis. J Nucl Med. 2013;54: 807-814.
40. Hansch A, Frey O, Sauner D, et al. In vivo imaging of experimental arthritis with near-infrared fluorescence. Arthritis Rheum. 2004;50: 961-967.
41. Fuchs K, Kohlhofer U, Quintanilla-Martinez L, et al. In vivo imaging of cell proliferation enables the detection of the extent of experimental rheumatoid arthritis by 39-deoxy-39-18f-fluorothymidine and small-animal PET. J Nucl Med. 2013;54: 151-158.
42. Kundu-Raychaudhuri S, Mitra A, Datta-Mitra A, Chaudhari AJ, Raychaudhuri SP. In vivo quantification of mouse autoimmune arthritis by PET/CT. Int J Rheum Dis. June 26, 2014 [Epub ahead of print].